ProCE Banner Activity

Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM

Slideset Download
Conference Coverage
APOLLO met its primary endpoint of significantly improved PFS with daratumumab SC + Pd vs Pd only in patients with relapsed/refractory MM previously treated with lenalidomide and a PI.

Released: December 10, 2020

Expiration: December 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology